Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company
will participate in three investor conferences during June.
Kevin T. Conroy, the company’s chairman and chief executive, will make
Exact’s presentation at the Jefferies 2014 Global Healthcare Conference
in New York at 1:30 p.m. ET on Tuesday, June 3.
Mr. Conroy also will participate in the William Blair 2014 Growth Stock
Conference in Chicago at 12 p.m. CT on Wednesday, June 11.
Mr. Conroy will make the company’s presentation at the JMP Securities
Healthcare Conference in New York at 1:30 p.m. ET on Wednesday, June 25.
A live webcast of each presentation will be available through the
company’s website at www.exactsciences.com.
An archived webcast will be available following the conclusion of each
conference.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the
early detection and prevention of colorectal cancer. The company has
exclusive intellectual property protecting its noninvasive, molecular
screening technology for the detection of colorectal cancer. Stool-based
DNA technology is included in the colorectal cancer screening guidelines
of the American Cancer Society and the U.S. Multi-Society Task Force on
Colorectal Cancer. For more information, please visit the company’s
website at www.exactsciences.com.
Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities and Exchange Act of
1934, as amended, that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of forward-looking
terms such as “believe,” “expect,” “may,” “will,” “should,” “could,”
“seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable
terms. Forward-looking statements in this news release may address the
following subjects among others: statements regarding the sufficiency of
our capital resources, expectations concerning our ability to secure and
the timing of FDA approval of and reimbursement for our Cologuard test,
our estimated reimbursement amounts, our estimates of the available
market size and our potential penetration, expected research and
development expenses, expected general and administrative expenses and
our expectations concerning our business strategy. Forward-looking
statements involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management’s
Discussion and Analysis of Financial Condition and Results of Operations
sections of our most recently filed Annual Report on Form 10-K and our
subsequently filed Quarterly Reports on Form 10-Q. We urge you to
consider those risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made. Except
as otherwise required by the federal securities laws, we disclaim any
obligation or undertaking to publicly release any updates or revisions
to any forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any change
in events, conditions or circumstances on which any such statement is
based.
Copyright Business Wire 2014